The 1 Number That Decides Whether a Dividend Lasts Your Whole Retirement
Most retirees obsess over yield and payout ratios, but neither metric has actually survived a recession, a rate spike, or a global pandemic on your behalf. One number has, and it changes everything about how you evaluate an income stock.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Yield gets the clicks. Payout ratio gets the analyst notes. But if you are trying to fund 30 years of retirement from a single stock, one metric outranks them all: the length of the dividend growth streak. It is the only number that has already survived every recession, rate cycle, and management change a retiree might live through.
Meet the Only Metric That Has Already Walked Through Fire
The metric is simple: how many consecutive years has the company raised its dividend? For Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction), the answer is 64 consecutive years, placing it deep into Dividend King territory. That streak is a stress test, run in real time, against stagflation, the 1987 crash, the dot-com bust, the 2008 financial crisis, COVID-19, talc litigation, the Kenvue spinoff and now an approximate 460 basis point headwind from Stelara biosimilar erosion.
Why This Number Beats Yield and Payout Ratio
Yield tells you what a stock pays today. Payout ratio tells you what it can afford this quarter, and the correct denominator (earnings, free cash flow, AFFO for REITs, net investment income for BDCs) changes by business model, so it is easy to misuse. A multi-decade streak tells you something neither can: management has treated the dividend as a contract across every macro regime a retiree will actually encounter.
Where the Streak Stands Right Now
In Q1 2026, the board approved a 3.1% dividend increase to $1.34 per share quarterly, up from $1.30. The forward annualized payout sits at $5.36. Cash flow backs it up. CFO Joe Wolk told investors JNJ is “on track for our full-year free cash flow outlook approaching $21 billion” against $12.38 billion in 2025 dividend payouts. Shares are up 31.11% year to date and 53.86% over the past year, trading at $271.86 on Sept. 24.
Bullish and Bearish Signals to Track Next
Bullish: free cash flow returning toward the $19.7 billion FY2025 run rate, oncology continuing to outrun Stelara (DARZALEX +22.5%, CARVYKTI +62.1%, TREMFYA +68.3%), and a 65th consecutive hike in early 2027. Bearish: litigation charges escalating beyond the $330 million booked in Q1, guidance cuts against the $11.45 to $11.65 adjusted EPS range, or a quarter where free cash flow falls short of the dividend obligation. Any of those would be the first crack in an otherwise pristine coverage picture.
Verdict for Retirement Portfolios
For retirees, the streak matters more than the headline yield of 1.94% because it is the only number that has already been tested against the exact conditions a thirty-year retirement will produce. Pair it with free cash flow coverage, and you have the closest thing public markets offer to a contract (we ranked ten Dividend Kings by valuation right now in a free report you can grab here). Break the streak, and the thesis breaks with it.
Contact [email protected] for any questions or corrections.
Joel South covers large-cap stocks, dividend investing, and major market trends, with a focus on earnings analysis, valuation, and turning complex data into actionable insights for investors.
He brings more than 15 years of experience as an investor and financial journalist, including 12 years at The Motley Fool, where he served as an investment analyst, Bureau Chief, and later led the Fool.com investing news desk. He has also co-hosted an investing podcast and appeared across TV and radio discussing market trends.
